A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Emmanuel Bachy,Steven Le Gouill,Roberta Di Blasi,Pierre Sesques,Guillaume Manson,Guillaume Cartron,David Beauvais,Louise Roulin,François Xavier Gros,Marie Thérèse Rubio,Pierre Bories,Jacques Olivier Bay,Cristina Castilla Llorente,Sylvain Choquet,René-Olivier Casasnovas,Mohamad Mohty,Stéphanie Guidez,Magalie Joris,Michaël Loschi,Sylvain Carras,Julie Abraham,Adrien Chauchet,Laurianne Drieu La Rochelle,Bénédicte Deau-Fischer,Olivier Hermine,Thomas Gastinne,Jean Jacques Tudesq,Elodie Gat,Florence Broussais,Catherine Thieblemont,Roch Houot,Franck Morschhauser
DOI: https://doi.org/10.1038/s41591-022-01969-y
IF: 82.9
2022-09-23
Nature Medicine
Abstract:Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study (NCT04328298). After 1:1 propensity score matching ( n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively ( P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46–0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45–0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1–2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade ≥3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1–2 and grade ≥3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.
biochemistry & molecular biology,cell biology,medicine, research & experimental